Oxylanthanum carbonate: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See NDA 218607's history or Unicycive Therapeutics's company page.
On Jun 29, 2026, FDA declined to approve Oxylanthanum carbonate (NDA 218607) from Unicycive Therapeutics Inc. in its present form, citing facility inspections. openFDA lists it as not yet approved.
- Letter date: Jun 29, 2026
- Application: NDA 218607
- Since then: Not approved
Following a Current Good Manufacturing Practices (CGMP) inspection of me listed in this application, FDA conveyed deficiencies โo the representative of the facility. The facility should provide satisfactory responses to hese deficiencies to the FDA office indi...โฆ openFDA did not return the full text just now. Open it in the letter search.
- Oxylanthanum carbonateJun 27, 2025 ยท NDA 218607 ยท not approved
- Company
- Unicycive Therapeutics Inc.
- Application
- NDA 218607
- Status in openFDA
- Unapproved
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters